Neoadjuvant sequencing, as seen in this trial could serve as a foundation for exploring the potential of neoadjuvant immunotherapy in PDL1-negative, locally advanced adenocarcinomas, for which treatment options are currently limited. This evidence concerns the gene CD274 and adenocarcinoma.